Search - tctmd.com

Displaying 41 - 48 of 48

Sort: Relevancy | Date

News Conference News AHA 2017

Novel Interatrial Shunt Succeeds in HF Hemodynamic Study: REDUCE LAP-HF I

Michael O'Riordan

November 21, 2017

News Conference News AHA 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

Shelley Wood

November 28, 2016

News Conference News AHA 2016

Interatrial Shunt Device Shows Sustained Improvement in Heart Failure Patients With Preserved EF

Shelley Wood

November 16, 2016

News Conference News AHA 2016

Intravenous Iron, Not Oral, Improves Functional Capacity in HF Patients

Michael O'Riordan

November 16, 2016

Presentation AHA 2016

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

Presenter: David M Kaye

November 15, 2016

News Conference News AHA 2016

The ART of CABG: Bilateral Technique Associated With Similar Outcomes as Single Graft at 5 Years

Yael L. Maxwell

November 14, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Conference News AHA 2012

EMPIRE: Exenatide Cardioprotective in STEMI Patients Receiving DES

Jason Kahn

November 04, 2012

Advertisement

Novel Interatrial Shunt Succeeds in HF Hemodynamic Study: REDUCE LAP-HF I

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

Interatrial Shunt Device Shows Sustained Improvement in Heart Failure Patients With Preserved EF

Intravenous Iron, Not Oral, Improves Functional Capacity in HF Patients

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

The ART of CABG: Bilateral Technique Associated With Similar Outcomes as Single Graft at 5 Years

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

EMPIRE: Exenatide Cardioprotective in STEMI Patients Receiving DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content